1. Home
  2. DOUG vs GBIO Comparison

DOUG vs GBIO Comparison

Compare DOUG & GBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DOUG
  • GBIO
  • Stock Information
  • Founded
  • DOUG 1911
  • GBIO 2016
  • Country
  • DOUG United States
  • GBIO United States
  • Employees
  • DOUG N/A
  • GBIO N/A
  • Industry
  • DOUG Building operators
  • GBIO Biotechnology: Pharmaceutical Preparations
  • Sector
  • DOUG Real Estate
  • GBIO Health Care
  • Exchange
  • DOUG Nasdaq
  • GBIO Nasdaq
  • Market Cap
  • DOUG 166.2M
  • GBIO 145.5M
  • IPO Year
  • DOUG N/A
  • GBIO 2020
  • Fundamental
  • Price
  • DOUG $1.66
  • GBIO $2.49
  • Analyst Decision
  • DOUG
  • GBIO Buy
  • Analyst Count
  • DOUG 0
  • GBIO 4
  • Target Price
  • DOUG N/A
  • GBIO $7.50
  • AVG Volume (30 Days)
  • DOUG 764.4K
  • GBIO 63.7K
  • Earning Date
  • DOUG 11-05-2024
  • GBIO 08-07-2024
  • Dividend Yield
  • DOUG N/A
  • GBIO N/A
  • EPS Growth
  • DOUG N/A
  • GBIO N/A
  • EPS
  • DOUG N/A
  • GBIO N/A
  • Revenue
  • DOUG $951,674,000.00
  • GBIO $13,174,000.00
  • Revenue This Year
  • DOUG $3.85
  • GBIO $99.36
  • Revenue Next Year
  • DOUG $17.40
  • GBIO N/A
  • P/E Ratio
  • DOUG N/A
  • GBIO N/A
  • Revenue Growth
  • DOUG N/A
  • GBIO 1397.05
  • 52 Week Low
  • DOUG $1.00
  • GBIO $0.86
  • 52 Week High
  • DOUG $3.16
  • GBIO $4.72
  • Technical
  • Relative Strength Index (RSI)
  • DOUG 44.02
  • GBIO 48.59
  • Support Level
  • DOUG $1.42
  • GBIO $2.13
  • Resistance Level
  • DOUG $1.91
  • GBIO $2.49
  • Average True Range (ATR)
  • DOUG 0.17
  • GBIO 0.24
  • MACD
  • DOUG -0.05
  • GBIO -0.02
  • Stochastic Oscillator
  • DOUG 29.56
  • GBIO 44.44

About DOUG Douglas Elliman Inc.

Douglas Elliman Inc is a real estate company. It offers sales, rentals, and new development to mortgages and title insurance, among other services related to real estate. Business is engaged in two operating segments Real Estate Brokerage and Corporate and other. The firm generates income from Commission and other brokerage revenue from existing home sales, Commission and other brokerage income from development marketing, Property management revenue and Title fees.

About GBIO Generation Bio Co.

Generation Bio Co is a genetics medicine company that is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina-related diseases. It is developing two distinct and complementary platforms that It believes will enable highly differentiated therapeutic applications. Its first platform is a potent, highly selective ctLNP delivery system for nucleic acids, which is designed to avoid off-target clearance by the liver and spleen, enabling ctLNPs to persist in systemic circulation and allowing for highly selective and potent ligand-driven targeting to specific tissues and cell types. Its second platform is its novel iqDNA, which is an optimized variant of its ceDNA.

Share on Social Networks: